Glycopyrrolate Inhalation for COPD
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an inhaled medication called glycopyrrolate to determine its effectiveness for people with COPD, a chronic lung disease that makes breathing difficult. Researchers aim to assess the safety and effectiveness of different doses compared to a placebo, which contains no active drug. Participants will try three different doses over separate weeks, with breaks in between, to identify the most effective dose. Suitable candidates have COPD symptoms that match specific guidelines and have smoked the equivalent of at least 10 cigarettes a day for 10 years. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.
Do I have to stop taking my current medications for the trial?
The trial requires participants to stop using short-acting bronchodilators for 4 hours and BID LABA ± ICS therapy for 24 hours before spirometry testing. Other medication requirements are not specified in the protocol.
Is there any evidence suggesting that glycopyrrolate inhalation is likely to be safe for humans?
Research has shown that inhaled glycopyrrolate is generally safe for people with COPD. Studies indicate it does not significantly increase the risk of heart or blood vessel issues compared to a placebo. In fact, individuals using nebulized glycopyrrolate have reported it to be safe for the heart.
Long-term studies have also found that using glycopyrrolate inhalation over time is as safe as other common COPD treatments. While some side effects might occur, they are usually mild and not serious. However, it is important to note that it should not be used during a severe COPD attack.
Overall, inhaled glycopyrrolate appears safe and is well-tolerated for treating COPD.12345Why do researchers think this study treatment might be promising for COPD?
Glycopyrrolate inhalation is unique because it offers a more targeted delivery method for treating COPD symptoms directly in the lungs. Unlike standard treatments like long-acting beta-agonists or corticosteroids, glycopyrrolate is an anticholinergic that works by blocking specific receptors in the airways, leading to relaxation and opening of the air passages. Researchers are excited about this treatment because it has the potential to provide fast relief with fewer systemic side effects, making it a promising option for those with COPD.
What evidence suggests that glycopyrrolate inhalation could be an effective treatment for COPD?
Research has shown that inhaled glycopyrrolate can help people with COPD. One study found that glycopyrrolate significantly improved lung function compared to a placebo, allowing patients to breathe better. Another study demonstrated that glycopyrrolate quickly opened the airways, easing breathing. These improvements were both statistically significant and clinically important, suggesting it could help people with COPD breathe more easily. Overall, evidence supports glycopyrrolate as a promising option for improving lung health in COPD patients.34678
Are You a Good Fit for This Trial?
This trial is for individuals with COPD, a type of obstructive lung disease. Participants will use a jet nebulizer to inhale the study medication or placebo twice daily for one week during different periods.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive glycopyrrolate inhalation solution or placebo for 1 week, followed by a 1-week washout period. This cycle is repeated for four treatment periods.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Glycopyrrolate
Trial Overview
The trial tests three doses of Glycopyrrolate (14 μg, 42.5 μg, and 85 μg) against a placebo to evaluate effectiveness and safety in managing COPD symptoms when administered via nebulizer over one-week treatment periods.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
Find a Clinic Near You
Who Is Running the Clinical Trial?
Verona Pharma plc
Lead Sponsor
Citations
Inhaled glycopyrrolate for the treatment of chronic obstructive ...
The GLOW1 study showed that glycopyrrolate 50 µg QD had a rapid onset of bronchodilation in patients with COPD, with a significant improvement ...
Impact of baseline clinical features on outcomes ...
This review highlights outcomes among subpopulations of patients with comorbidities (eg, anxiety/depression, cardiovascular disease), and their impact on the ...
Comparative Study on the effectiveness of Glycopyrrolate ...
Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease.
Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized ...
The results of these studies demonstrated statistically significant and clinically important improvements in pulmonary function and patient- ...
5.
journal.copdfoundation.org
journal.copdfoundation.org/jcopdf/id/1099/Efficacy-and-Safety-of-Twice-Daily-Glycopyrrolate-Versus-Placebo-in-Patients-With-COPD-The-GEM2-StudyEfficacy and Safety of Twice-Daily Glycopyrrolate Versus ...
Compared with placebo, glycopyrrolate showed significant improvements in lung function parameters (p<0.001). Health status (SGRQ total score and COPD assessment ...
Safety of inhaled glycopyrronium in patients with COPD
Furthermore, glycopyrronium did not result in an increased risk of cerebro-cardiovascular events vs placebo. There were no new safety reports ...
7.
mayoclinic.org
mayoclinic.org/drugs-supplements/glycopyrrolate-inhalation-route/description/drg-20165175Glycopyrrolate (inhalation route) - Side effects & dosage
Safety and efficacy have not been established. ... COPD attack, severe—Should not be used if you are having a severe COPD attack, or if symptoms ...
Long-term safety of glycopyrrolate: A randomized study in ...
GEM3 was a long-term safety (52 weeks) study in patients with COPD. · Long-term safety of glycopyrrolate 15.6 μg b.i.d. was comparable to indacaterol 75 μg q.d..
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.